The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
Hemophilia A and hemophilia B are genetic bleeding disorders ... leading to an increase in thrombin, an enzyme critical for blood clotting. Qfitlia is administered under the skin (subcutaneously) ...
The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...
The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare bleeding disorder.
Some types, such as hemophilia, are inherited ... These genes contain instructions for how to make proteins in the blood called clotting factors, which help blood clot. If there is a problem ...
Pharmaceuticals highlighted the significance of the FDA approval of Qfitlia, the sixth Alnylam-discovered RNAi therapeutic ...
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
"Today's approval of Qfitlia is significant for patients with hemophilia because it can ... has a boxed warning for thrombotic events (blood clotting) and gallbladder disease (with some patients ...
About 3 million people in the U.S. have bleeding disorders. Some types, such as hemophilia, are inherited, meaning a person who has it is born with it. Inherited bleeding disorder ...